Abstract
Many neurodegenerative disorders, including Alzheimer’s disease (AD), are strongly associated with the accumulation of oxidative damage. Transgenic animal models are commonly used to elucidate the pathogenic mechanism of AD. Beta amyloid (Aβ) and tau hyperphosphorylation are very famous hallmarks of AD and well-studied, but the relationship between mitochondrial dysfunction and the onset and progression of AD requires further elucidation. In this study we used transgenic mice (the strain name is 5xFAD) at three different ages (3, 6, and 20 months old) as an AD model. Cognitive impairment in AD mice occurred in an age-dependent manner. Aβ1-40 expression significantly increased in an age-dependent manner in all brain regions with or without AD, and Aβ1-42 expression in the hippocampus increased at a young age. In a Western blot analysis using isolated mitochondria from three brain regions (cerebral cortex, cerebellum, and hippocampus), NMNAT-3 expression in the hippocampi of aged AD mice was significantly lower than that of young AD mice. SOD-2 expression in the hippocampi of AD mice was lower than for the age-matched controls. However, 3-NT expression in the hippocampi of AD mice was higher than for the age-matched controls. NQO-1 expression in the cerebral cortex of AD mice was higher than for the age-matched controls at every age that we examined. However, hippocampal NQO-1 expression in 6-month-old AD mice was significantly lower than in 3-month-old AD mice. These results indicate that oxidative stress in the hippocampi of AD mice is high compared to other brain regions and may induce mitochondrial dysfunction via oxidative damage. Protection of mitochondria from oxidative damage may be important to maintain cognitive function.
Highlights
Calcium homeostasis is disrupted, and mitochondrial oxidation is induced [23]. These results indicate that mitochondrial dysfunction via oxidation is strongly related to the onset and progression of Alzheimer’s disease (AD)
The goal time gradually decreased for all mouse groups
The goal time gradually decreased for all mouse groups with or without
Summary
Alzheimer’s disease (AD) is a severe irreversible brain disorder. The number of patients suffering from it in Japan is currently higher than 3 million, and the rate of its increase there is the fastest in the world [1]. The most important symptom of AD is dementia via dysfunction of cholinergic neurons [2]; in particular, neuronal cell death occurs frequently in the hippocampal region [3]. An AD therapeutic, acts as an inhibitor of acetylcholine esterase [4], but because treatment with donepezil does not stop AD progression [5], the development of novel therapeutic agents is necessary
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.